| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pharmacology and Toxicology* and Ophthalmology, the Vascular Biology Center, Cellular Biology and Anatomy, and the Medical College of Georgia; and the Veterans Affairs Medical Center, Augusta, Georgia
Diabetic retinopathy is characterized by blood-retinal barrier (BRB) breakdown and neurotoxicity. These pathologies have been associated with oxidative stress and proinflammatory cytokines, which may operate by activating their downstream target p38 MAP kinase. In the present study, the protective effects of a nonpsychotropic cannabinoid, cannabidiol (CBD), were examined in streptozotocin-induced diabetic rats after 1, 2, or 4 weeks. Retinal cell death was determined by terminal dUTP nick-end labeling assay; BRB function by quantifying extravasation of bovine serum albumin-fluorescein; and oxidative stress by assays for lipid peroxidation, dichlorofluorescein fluorescence, and tyrosine nitration. Experimental diabetes induced significant increases in oxidative stress, retinal neuronal cell death, and vascular permeability. These effects were associated with increased levels of tumor necrosis factor-
, vascular endothelial growth factor, and intercellular adhesion molecule-1 and activation of p38 MAP kinase, as assessed by enzyme-linked immunosorbent assay, immunohistochemistry, and/or Western blot. CBD treatment significantly reduced oxidative stress; decreased the levels of tumor necrosis factor-, vascular endothelial growth factor, and intercellular adhesion molecule-1; and prevented retinal cell death and vascular hyperpermeability in the diabetic retina. Consistent with these effects, CBD treatment also significantly inhibited p38 MAP kinase in the diabetic retina. These results demonstrate that CBD treatment reduces neurotoxicity, inflammation, and BRB breakdown in diabetic animals through activities that may involve inhibition of p38 MAP kinase.
This article has been cited by other articles:
 |
|
 |
|
  M. Al-Shabrawey, M. Bartoli, A. B. El-Remessy, G. Ma, S. Matragoon, T. Lemtalsi, R. W. Caldwell, and R. B. Caldwell Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3231 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Ali, S. Matragoon, B. A. Pillai, G. I. Liou, and A. B. El-Remessy Peroxynitrite Mediates Retinal Neurodegeneration by Inhibiting Nerve Growth Factor Survival Signaling in Experimental and Human Diabetes Diabetes, April 1, 2008; 57(4): 889 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. El-Remessy, M. Al-Shabrawey, D. H. Platt, M. Bartoli, M. A. Behzadian, N. Ghaly, N. Tsai, K. Motamed, and R. B. Caldwell Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells FASEB J, August 1, 2007; 21(10): 2528 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, V. R. Drel, I. G. Obrosova, and P. Pacher Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H610 - H619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Novak, D. Last, D. C. Alsop, A. M. Abduljalil, K. Hu, L. Lepicovsky, J. Cavallerano, and L. A. Lipsitz Cerebral Blood Flow Velocity and Periventricular White Matter Hyperintensities in Type 2 Diabetes Diabetes Care, July 1, 2006; 29(7): 1529 - 1534. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
